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Abstract: Pancreatic cancer has become the third leading cause of cancer-related death in the
Western world despite advances in therapy of other cancerous lesions. Late diagnosis due to
a lack of symptoms during early disease allows metastatic spread of the tumor. Most patients
are considered incurable because of metastasized disease. On a cellular level, pancreatic cancer
proves to be rather resistant to chemotherapy. Hence, early detection and new therapeutic targets
might improve outcomes. The detection of DNA promoter hypermethylation has been described
as a method to identify putative genes of interest in cancer entities. These genes might serve as
either biomarkers or might lead to a better understanding of the molecular mechanisms involved.
We checked tumor specimens from 80 patients who had undergone pancreatic resection for promoter
hypermethylation of the zinc finger protein ZNF154. Then, we further characterized the effects
of ZNF154 on cell viability and gene expression by in vitro experiments. We found a significant
association between ZNF154 hypermethylation and better survival in patients with resectable
pancreatic cancer. Moreover, we suspect that the cell growth suppressor SLFN5 might be linked to a
silenced ZNF154 in pancreatic cancer.
Keywords: pancreatic cancer; PDAC; ZNF154; SLFN5; DNA methylation; methylation-specific
PCR; biomarker
1. Introduction
Pancreatic cancer remains one of the deadliest cancer types with an estimated median 5-year
survival rate of only 3% [1]. More than 90% of pancreatic cancers are diagnosed in patients 55 years
of age or older [2] and the incidence is projected to rise in the future [3]. The term pancreatic cancer
usually refers to pancreatic ductal adenocarcinoma (PDAC). This histologic type represents about
90% of all pancreatic cancers and originates from the ductal epithelium of the exocrine pancreatic
portion [4]. Other types of pancreatic cancer include forms that arise from the exocrine part as well,
e.g., acinar cell carcinoma, or tumors that emerge from different parts, e.g., neuroendocrine tumors.
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The causes of PDAC are still not completely understood. There is evidence for certain risk factors,
such as tobacco smoking, chronic pancreatitis, positive family history, longstanding diabetes mellitus,
or obesity [2]. Symptoms are sparsely found in patients with early disease. Unspecific findings, such
as weight loss or abdominal pain, make this entity hard to diagnose [5].
The grim prognosis is due to several factors. Late diagnosis, unavailability of screening,
retroperitoneal location of the pancreas, and advanced age of patients offer limited therapeutic
options. On a molecular and cellular level, PDCA exhibits aggressive growth and resistance to
chemotherapeutic agents [6]. Despite more than 50 years of research, advances in therapy and,
ultimately, improvements of outcomes have been small. However, Yachida et al. [7] found that there is
a latency period of at least 15 years for evolution from a single PDAC cell to metastatic tumor growth.
Therefore, there may be ample time to diagnose and possibly cure patients with a tailored therapy if
the tumor is caught at a very early stage and if its molecular characterization is understood well.
In previous studies, we proposed analysis of hypermethylation in tumor tissue as a means to
spot putative genes of interest [8,9]. Recent research has disclosed DNA promoter hypermethylation
of the zinc finger protein ZNF154 in a variety of tumor cell lines [10]. We hypothesized that the
ZNF154 promoter is hypermethylated in vitro as well as in vivo. More specifically, we aimed to
analyze pancreatic tumor tissue samples from patients who received pancreatic resection for ZNF154
hypermethylation and to further characterize the effect of ZNF154 hypermethylation in vitro.
2. Results
2.1. Promoter Hypermethylation Analysis in Different Cell Lines
We aimed to analyze the ZNF154 methylation status of different established cell lines. Purified
DNA samples were extracted and subjected to sodium bisulfite conversion. PCRs using HB14
primers were performed to distinguish between true-positive sodium bisulfite-converted samples
and false-positive hypermethylation status [9,10]. Samples that showed successful amplification were
approved for methylation-specific PCR analysis. We found that, among other cell lines, the PANC-1 cell
line was positive for hypermethylation (Figure 1a). HPDE-E6E7 cells are normal, immortalized ductal
epithelial cells [11]. In our analysis, we discovered that these cells were negative for hypermethylation.
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Figure 1. (a) Exemplary image of PCR gel el ctrophoresis checking ZNF154 hypermethylation in
differ nt cell lines (AsPC-1 cells, CAPAN-1 cells, CAPAN-2 cells, HPDE-E6E7 cells, MIA PaCa-2 cells,
PANC-1 cells, TM3M4 cells; = marker at 200 and 100 bp, EC = empty control). (b) Relative expression
levels of RNA coding for ZNF154 found in different cell lines compared to that in HPDE-E6E7 cells
(dotted line = mean relative expression of 2.3%).
Hypermethylation of the ZNF154 promoter region had a strong inverse correlation to transcription
of ZNF154 RNA [10]. We checked levels of expression of RNA coding for ZNF154 in the
above-mentioned cell lines by performing real-time PCR. A ratio was calculated using the HPDE-E6E7
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expression levels, which were assumed to exhibit expression levels of 100%. PANC-1 cells had a relative
expression level of less than 2.3% compared to RNA levels found in HPDE-E6E7 cells (Figure 1b).
2.2. Patient Collective
Pancreatic specimens were obtained from patients undergoing pancreatic resection due to
pancreatic ductal adenocarcinoma. In total, 86 patients were initially included. Exclusion criteria
were insufficient DNA concentration of sample (< 2 ng/µL), incomplete bisulfate conversion, missing
data, loss to follow-up, or postoperative survival of less than 14 days. After applying exclusion
criteria, a total of 80 patients remained in the final patient collective for further examination. Table 1
demonstrates patient characteristics of this patient collective. The most common tumor size was pT3
(83.3%), with most patients having positive lymph node status (pN1 = 67.5%) while not suffering
from metastasized disease (pM0 = 91.3%). Accordingly, AJCC tumor stage IIb was the most common
(58.8%). Tumor differentiation found in samples was mostly classified as G2 (52.5%) or G3 (41.3%).
The mean patient age was 66 years, with a mean survival of 707 days following resection.
Table 1. Patient characteristics of the patient collective.
Patient Characteristics Absolute Relative
Gender (male/female) 42/38 52.5%/47.5%
TNM classification
pT1 1 1.3%
pT2 10 12.5%
pT3 67 83.8%
pT4 2 2.5%
pN0 26 32.5%
pN1 54 67.5%
pM0 73 91.3%
pM1 4 5%
pMx 3 3.8%
AJCC stages (7th edition)
Ia - -
Ib 5 6.3%
IIa 20 25%
IIb 47 58.8%
III 1 1.3%
IV 4 5%
unknown 3 3.8%
Histologic grades
G1 3 3.7%
G2 42 52.5%
G3 33 41.3%
G4 2 2.5%
Mean Minimum Maximum
Patient age at time of surgery (years) 65.7 40 80
Postoperative survival (days) 707.2 17 4190
2.3. Methylation Status of ZNF154 Promoter in Patient Specimens
Specimens were subjected to bisulfite conversion and then analyzed using methylation-specific
PCR. PANC-1 DNA was used as a positive control while DNA from HPDE-E6E7 cells served as a
negative control. A total of 59 (73.75%) patients exhibited positive ZNF154 promoter methylation
(MSP-positive) while only 21 (26.25%) patients did not have promoter methylation (MSP-negative).
After analysis using the log rank test, we found that there was a significant correlation between the
status of ZNF154 promoter hypermethylation and postoperative survival: MSP-positive patients had a
markedly increased postoperative survival, with a median of 652 days, versus MSP-negative patients,
who had a median postoperative survival of 392 days. Other clinical parameters, such as gender, age
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at the time of procedure, tumor size, histologic grading, status of lymph node, or distant metastasis,
were not significantly correlated. Data are shown in Figure 2 and Tables 2 and 3.
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Figure 2. Kaplan–Meier plot for pancreatic cancer postoperative survival stratified by methylation-
specific PCR (MSP) results concerning the status of ZNF154 methylation (n = 80, p = 0.004).
Table 2. Logrank test analysis results for median postoperative survival (days) according to
methylation-specific PCR (MSP) status of ZNF154 (n = 80, SE = standard error).
MSP Days SE
95% Confidence Level
Lower Limit Upper Limit
Negative 392 94 209 575
Positive 652 101 454 850
Total 583 67 452 714
Table 3. Clinical parameters and their respective strength of association for survival in our patient
collective (MSP = methylation-specific PCR).
Parameters Definition p-Value Odds Ratio
95% Confidence Level
Lower Limit Upper Limit
Gender 0 = female1 = male 0.098 0.617 0.348 1.093
Patient age at the time of surgery metric 0.268 0.982 0.952 1.014
Tumor size pT1/2 = 1pT3/4 = 2 0.308 0.613 0.239 1.571
Lymph node status pN0 = 0pN1 = 1 0.230 1.472 0.783 2.769
Metastases pM0 = 0pM1 = 1 0.208 0.498 0.168 1.475
Histologic grade G1/2 = 1G3/4 = 2 0.115 1.588 0.894 2.822
MSP status negative = 0positive = 1 0.002 0.392 0.215 0.715
2.4. In Vitro Viability Assays
The effect of ZNF154 hypermethylation on a cellular level was further characterized by in vitro
experiments. Transient transfections with plasmids holding ZNF154-DNA were performed in four
different cell lines. Automated cell counts of vital cells were conducted subsequent to transfections.
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PANC-1, AsPC-1, and BxPC-3 cells were used in the promoter hypermethylation analysis described
above and are human pancreatic cancer cell models. While BxPC-3 is a wildtype, PANC-1 and AsPC-1
both carry a KRAS mutation. TB32047 is a murine pancreatic tumor cell line with a KRAS mutation.
Transfections with the ZNF154 plasmid caused a significant reduction (p < 0.01) of vital cells in all
cell lines after 24 and 48 h compared to the negative control (empty vector). The most prominent
reduction of living cells was observed in BxPC-3 cells, as depicted in Figure 3. The efficiency of transient
transfections was monitored by transfecting a plasmid (pcz-CFG5.1) coding for green fluorescent
protein (GFP). The percentage of detected GFP in transfected cells ranged from 54% to 85%, which we
judged as sufficient.
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2.5. Quantification of RNA Transcript and Transcript Sequencing
Transfected cells were analyzed with quantitative real-time PCR (qPCR) to check for levels of
RNA expression. There was significant increase in the expression of ZNF154-RNA in all cell lines,
which was most prominent after 24 and 48 h. The ∆∆CT values were −17 ± 3 at 24 h and −20 ± 3 at
48 h in PANC-1 cells, −18 ± 2 at 24 and 48 h in AsPC-1 cells, −18 ± 4 at 24 h and −19 ± 3 at 48 h in
BxPC-3 cells, and −20 ± 4 at 24 h and −17 ± 4 at 48 h in TB32047 cells (Figure 4).
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Sequencing was done with PANC-1 cells and AsPC-1 cells that had been transfected with either
the ZNF154-plasmid or the pcz-CFG5.1-plasmid. Further gene analysis was performed on genes that
exhibited a significant log2 fold change ≥ +2 or ≤ −2 following transfection. As a result, we identified
three genes for further analysis: SLFN5, TNFSF10, and LTB. SLFN5 was identified to have increased
expression (PANC-1 + 2.5, AsPC-1 + 2.6). ZNF154 revealed a strong induction in accordance with
the prior results of qPCR. Data are displayed in Table 4. For confirmatory RNA quantitation, we
conducted qPCR following transient transfection with ZNF154 in the aforementioned cell lines. It was
revealed that expression of LTB was increased, not decreased, in PANC-1 cells after 48 h. Results for
the expression of LTB in other cell lines or of TNFSF10 in any cell line were not significant. There was a
significant induction of SLFN5 in PANC-1 and AsPC-1 cells after 24 h and also in BxPC-3 cells after
48 h.
Table 4. Sequencing results in either PANC-1 or AsPC-1 cells for the genes of interest SLFN5, TNFSF10,
LTB, and ZNF154.
Gene PANC-1log2 Fold Change
PANC-1
p-Value
AsPC-1
log2 Fold Change
AsPC-1
p-Value
ZNF154 9.338 0.0001 13.187 0.0032
SLFN5 2.453 0.0001 2.259 0.0002
TNFSF10 −3.932 0.0009 −1.513 0.0345
LTB −1.288 0.0139 −5.342 0.0355
2.6. Protein Expression
We further investigated if transient transfections with the ZNF154 plasmid would affect protein
levels of SLFN5. Transfections with empty controls, the ZNF154 plasmid, and the pcz-CFG5.1 plasmid
as positive controls were carried out in PANC-1 cells. The SLFN5 protein runs were at 101 kDa.
In PANC-1 cells, the SLFN5 band emitted a more intense signal as compared to controls after 24 and
48 h (Figure 5).
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3. Discussion
Pancreatic cancer resembles an aggressive tumor with poor prognosis. The short survival is mostly
due to the lack of effective therapeutic means and late diagnosis. In earlier publications, we suggested
an examination of pancreatic tumor cells for aberrant DNA methylation in order to identify novel
molecular markers [8,9]. Sánchez-Vega et al. [10] confirmed methylation of the gene ZNF154 in a
variety of solid tumors. ZNF154 encodes for a zinc-finger protein. Since zinc-finger proteins are, among
other functions, involved in transcriptional activation and regulation of apoptosis [12], ZNF154 has
piqued our interest.
In the current study, we demonstrated that the ZNF154 promoter was hypermethylated in many
pancreatic cell lines. This finding led to the assumption that ZNF154 hypermethylation might also be
present in pancreatic cancer patients.
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To investigate a possible presence of ZNF154 hypermethylation in vivo, we analyzed pancreatic
cancer specimens from 80 patients. The patient collective reflects a typical surgical patient group.
Almost three quarters (73.75%) of the patient collective had ZNF154 promoter hypermethylation. When
we analyzed the patient data for the clinical course, we found a significant association between ZNF154
promoter hypermethylation and better postoperative survival (Figure 3, Tables 2 and 3). A recent
study has shown that ZNF154 methylation was associated with better survival in nasopharyngeal
carcinoma [13]. In contrast, a different research group reported poor outcomes in loss of function
of ZNF154 in prostate cancer [14]. Generally, ZNF154 promoter hypermethylation has been found
in several cancer entities and was suggested for screening [10,15–18]. Pancreatic cancer is usually
diagnosed at a late stage. This is due to the occurrence of little symptoms during the initial progress
of the disease [19,20]. Hence, the usefulness of ZNF154 in screening for pancreatic cancer should be
reassessed with a different patient collective for this matter. Few publications, however, have been
able to implicate the prognostic value of ZNF154. In the present study, we demonstrated a positive
correlation between silenced ZNF154 and prolonged survival in resectable pancreatic cancer patients.
Future research in different tumor entities should target patient survival in relation to methylated
ZNF154 as well.
The fact that ZNF154 promoter hypermethylation was the single factor associated with survival
in our study underlines the need to investigate the basic molecular mechanisms of this disease. We
evaluated the effects of ZNF154 in vitro with transient transfections in cells that were associated with a
suppression of the ZNF154 promoter. We found that the artificial re-induction of ZNF154 by transient
transfections in these cells led to increased cell death compared to transfected controls. While KRAS
mutation status was independent of this finding, we demonstrated increased ZNF154 RNA levels in all
cell lines. Generally, cell death or apoptosis is a mechanism of anti-cancer defense. However, cell death
also increases pressure on clonal selection and ultimately contributes to higher sub-clonal variability.
The current literature suggests that generated tumor evolution by cell death is associated with higher
chemoresistance, more aggressive tumor progression, and a higher chance of tumor relapse [21]. Hence,
silencing of ZNF154 might foster the growth of more stable, less aggressive tumor clones.
Complete sequencing of ZNF154 over-expressing cells disclosed three putative genes of interest.
Further testing indicated a role for the gene SLFN5. Results for the remaining two genes were
ambiguous or insignificant. Transfecting cells with ZNF154 induced significantly increased expression
of SLFN5 code as well as SLFN5 protein. Hence, we argue that SLFN5 might play a role in pancreatic
cancer and is connected to up- or downregulation of the ZNF154 gene.
SLFN5 is a member of the Schlafen family (Slfn) genes. These genes typically exhibit anti-neoplastic
effects and are upregulated in response to interferon. The precise molecular mechanisms of SLFN5
are unclear while its role in tumor growth has been fairly characterized. Few studies observed a
positive correlation between SLFN5 and shorter overall survival [22,23]. Yet, most authors report a
connection between SLFN5 and longer survival or less invasive growth, underlining that SLFN5 is
a tumor suppressor [24–27]. These findings concur with our observation that increased survival in
pancreatic cancer patients is linked to silenced ZNF154, which, in turn, might translate into lower
levels of SLFN5.
Taken together, we are the first, to our best knowledge, to report an association between
hypermethylation of the ZNF154 promoter and better survival in resectable pancreatic cancer. Moreover,
we suspect a link between a silenced ZNF154 and SLFN5 in pancreatic cancer. However, the exact
mechanism between ZNF154 and SLFN5 remains to be elucidated.
4. Materials and Methods
4.1. Cell Culture
HPDE-E6E7 cells were a gracious gift from Dr. Ming Tsao, Toronto, Canada. TB32047 cells were a
gracious gift from Dr. David Tuveson, CSHL, New York, NY, USA. PaCaDD cell lines were already
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available at the Research Laboratory of the Department for Visceral-, Thoracic-, and Vascular Surgery,
University Hospital Carl Gustav Carus Dresden, Germany. All other cell lines were commercially
acquired from ATCC, USA.
AsPC-1 cells and BxPC-3 cells were grown in RPMI 1640 medium supplemented with 10 mM
Hepes, 1 mM sodium pyruvate, 4.5 g/L glucose, and 10% fetal bovine serum (FBS). TB32047 cells
were grown in DMEM supplemented with 10% FBS. PANC-1 cells were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum. All other cell lines were grown in either standard cell
medium or in medium as recommended by the manufacturer. For transfer to further testing, cells were
washed with DPBS, lysed with Trypsin-EDTA (0.25%) for 10 min, and suspended in FBS.
4.2. Patient Specimens
The study was conducted at the Department for Visceral-, Thoracic-, and Vascular Surgery,
University Hospital Carl Gustav Carus Dresden, Germany. It was reviewed by the Ethics Commission
(EK59032007) and was conducted ethically in accordance with the World Medical Association
Declaration of Helsinki. All experiments adhered to the German Genetic Engineering Act (project
number 55-8811.72/83/301 1 August 2002) as well as the data confidentiality principles of the Medical
Faculty of the Technical University Dresden and the University Hospital Carl Gustav Carus Dresden.
Informed consent to provide tissue for research and publication purposes was obtained from all
participants prior to surgery.
To be included in the patient cohort, tissue samples had to be from patients diagnosed with
ductal adenocarcinoma of the pancreas who received pancreatic resection at the University Hospital
Carl Gustav Carus Dresden. Exclusion criteria were an insufficient DNA concentration of the sample
(<2 ng/µL), incomplete bisulfate conversion, missing data, loss to follow-up, or postoperative survival
of less than 14 days. Patient specimens were stored at the Biobank of the University Cancer Center of
the University Hospital Carl Gustav Carus Dresden, Germany.
4.3. Methylation-Specific PCR (MSP) with Tumor Specimens and Cell Lines
Patient samples were either received as cryopreserved or paraffin-embedded tissue sections. These
sections were probed using a 20-G needle. Cells from cell culture were collected after the lysis procedure
described above and centrifuged. The resulting cell pellets were collected and washed with DPBS.
Tissues or cell pellets were transferred into 1.5-mL Eppendorf tubes with 180 µL of ATL buffer and
20 µL of Proteinase K. Tubes were incubated on a thermo-shaker for 3 h at 56 ◦C and 700 rpm. In total,
4 µL of RNase A (100 mg/mL) was added and probes were incubated for 2 min at room temperature.
Then, 200 µL of AL buffer was added and probes were incubated on a thermo-shaker for 10 min at
70 ◦C and 700 rpm. Next, 200 mL of ethanol (96–100%) was added and the lysates were transferred
into QIAamp Mini columns (Qiagen, Hildesheim, Germany). Further DNA purification was carried
out by following the instructions of the manufacturer. The final DNA suspension was transferred into
1.5-mL Eppendorf tubes, the DNA concentration was quantified by absorbance measurement, and
tubes were stored at −20 ◦C.
Bisulfite treatment was accomplished using the EZ DNA Methylation-Gold Kit (Zymo, Freiburg,
Germany) according to the manufacturer′s instructions.
For MSP, 20 ng of converted DNA aliquots were transferred in 0.5-mL Eppendorf tubes. Every
MSP series included PANC-1 DNA as the positive control, HPDE6E7c7 DNA as the negative control as
well as a master mix as the empty control. To exclude unsuccessful bisulfate conversion, we compared
each MSP run with additional amplification results using HB14 primers [28]. Primer sequences and
PCR cycler settings are available from the authors on request.
4.4. Quantitative Real-Time PCR (qPCR) of mRNA
Supernatant was taken from cell cultures, washed with PBS, and pipetted in 24-well plates. Further
mRNA purification was accomplished using the miRNeasy Mini kit following the instructions of the
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manufacturer (Qiagen, Hildesheim, Germany). The obtained RNA samples were transcribed and
amplified using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher, Langenselbold,
Germany) according to the manufacturer′s instructions. The final aliquots for qPCR were composed of
12.5 µL of Power SYBR Green Master Mix (ThermoFisher, Langenselbold, Germany), 2.5 µL of forward
primer, 2.5 µL of reverse primer, 0.5 µL of DEPC-H2O, and 2 µL of cDNA. Housekeeping gene ACTB
primers were used for normalization. qPCR was performed with the StepOne Real Time PCR System.
Analysis was done with the Step One software (ThermoFisher, Langenselbold, Germany). Primer
sequences are available from the authors on request.
4.5. Transient Transfections
Cell cultures were washed with DPBS and lysed with trypsin-EDTA. Approximately 3 × 104
cells per well were plated with 500 µL of cell culture medium in 24-well plates and incubated for
24 h. The pcz-CFG5.1 plasmid was a gracious gift from Prof. Dr. Achim Temme, Dresden, Germany.
All other plasmids were commercially acquired from Source Bioscience (Nottingham, UK) (clone
accession BC160120 in poLEYFP-C1am vector) and were prepared with the Qiagen EndoFree Plasmid
kit according to the manufacturer′s instructions (Qiagen, Hildesheim, Germany). Empty controls were
solely treated with 100 µL of Opti-MEM medium (ThermoFisher, Langenselbold, Germany). ZNF154
plasmid aliquots were prepared with 91 µL of Opti-MEM, 1 µL of Lipofectamine 2000 (ThermoFisher,
Langenselbold, Germany), and 8 µL (100 ng/µL) of ZNF154 DNA plasmid. Plasmid controls were
prepared with 91 µL of Opti-MEM, 1 µL of Lipofectamine, and 8 µL (100 µg/µL) of pcz-CFG5.1 DNA
plasmid. Following transfection, wells were incubated for 20 min at room temperature and analyzed
after 6, 12, 24, 48, and 72 h for cell count, gene, and protein expression.
4.6. Cell Viability Assessment
Supernatant was removed. Cells were washed with 500 µL of DPBS, lysed in 150 µL of
trypsin-EDTA, and resuspended in 500 µL of cell culture medium. Samples of 10 µL were transferred
onto glass slides and analyzed with a TC20 Automated Cell Counter. Samples with cell counts below
5 × 104 cells/mL were verified manually with a Neubauer slide.
4.7. RNA Sequencing
PANC-1 cells and AsPC-1 cells were analyzed after transient transfections with next-generation
sequencing. mRNA was isolated from 1.5 ug of DNAse-treated total RNA using the Globin-Zero Gold
rRNA Removal Kit (human, mouse, rat) from Illumina according to the manufacturer′s instructions.
After elution in nuclease free water, a second poly-A targeted mRNA isolation using the NEBnext
mRNA Magnetic Isolation Module (New England Biolabs GmbH; Frankfurt am Main Germany) was
performed. Samples were then directly subjected to the workflow for strand specific RNA-Seq library
preparation (Ultra Directional RNA Library Prep, NEB). For ligation, custom adaptors were used 1:
(Adaptor-Oligo 5′-ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT-3′, Adaptor-Oligo 2:
5′-p-GAT CGG AAG AGC ACA CGT CTG AAC TCC AGT CAC-3′). In the following PCR enrichment
(15 cycles), custom amplification primers were used carrying the index sequence indicated with
′NNNNNN′. (Primer1: Oligo_Seq AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC
CTA CAC GAC GCT CTT CCG ATC T, primer2: GTG ACT GGA GTT CAG ACG TGT GCT CTT
CCG ATC T, primer3: CAA GCA GAA GAC GGC ATA CGA GAT NNNNNN GTG ACT GGA
GTT. After XP bead purification, libraries were quantified using the Qubit dsDNA HS Assay Kit
(ThermoFisher, Langenselbold, Germany), equimolarly pooled, and subjected to 75-bp single read
sequencing on Illumina HiSeq 2500. RNA sequences were compared to the GRCh37 human reference
genome using the Genomic Short-read Nucleotide Alignment Program [29]. RNA reads were counted
with featureCounts [30] and analyzed for differential expression with DeSeq2 [31]. Significant findings
were studied with PANTHER and WebGestalt [32,33].
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4.8. Western Blots
Supernatant was removed. Cells were washed with 500 µL of DPBS, lysed in 150 µL of trypsin,
incubated for 10 min at 37 ◦C, and resuspended in their specific cell culture medium. Aliquots of
1.5 mL each were prepared with collected cells in Eppendorf tubes and centrifuged at 3000× g for
5 min at room temperature. Supernatant was removed, cell pellets were washed with 500 µL of DPBS,
and centrifuged at the same settings again. The cell pellets were buffered in 30 to 50 µL of RIPA
buffer (containing protease inhibitor 1:100, phosphate inhibitor 1:100), put on ice for 30 min, treated
in an ultrasound bath for 10 min, and centrifuged at 11,000× g at 4 ◦C for 20 min. The supernatant
was collected in 1.5-mL Eppendorf tubes. Colorimetric determination of the protein concentration
was achieved with a BCA Protein Assay (ThermoFisher, Langenselbold, German) according to the
manufacturer′s instructions. In total, 10 µg of protein solved in RIPA buffer was mixed with 5 µL
of 4 × NuPage LDS sample buffer, 2 µL of 10 × NuPage LDS reducing agent, and 1 × NuPage LDS
sample buffer to a total volume of 25 µL each. Samples were incubated for 10 min at 90 ◦C in a thermo
mixer and loaded onto 4–12% Bis-Tris polyacrylamide gels in XCell SureLock Mini-Cell chambers
(ThermoFisher, Langenselbold, German). Mini cells were filled with NuPage antioxidant, Precision
Plus Protein All Blue-Standards, and running buffer according to the manufacturer′s instructions.
Samples were separated at 180 V for 55 min. Gels were electroblotted onto nitrocellulose membranes at
30 V for 60 min in XCell SureLock Mini-Cell systems. Blots were stained with Ponceau S and washed
with TBST. After blocking in TBST wash (2.5 g of instant milk, 50 mL of TBST) overnight at 4 ◦C, the
membranes were probed with primary antibodies. GAPDH antibodies (Cell Signaling Technology Cat#
2118, RRID: AB_561053; 1:1000 in 5% BSA) were applied at room temperature for 1 h. SLFN5 antibodies
(Santa Cruz Biotechnology; sc-240891; 1:1000 in 5% BSA) were applied at 4 ◦C overnight. Blots were
washed with TBST and incubated with corresponding secondary antibodies ((R and D Systems Cat#
HAF109, RRID: AB_357236 for SLFN5 and Cell Signaling Technology Cat# 7074, RRID: AB_2099233 for
GAPDH; 1:1000 in 5% non-fat milk) for 1 h at room temperature. Blots were washed again with TBST
and incubated with horseradish peroxidase and luminol (1:1, approximately 0.1 mL/cm2) reactant for
5 min. Signal detection was performed with a G: BOX XT4 (Syngene, Cambridge, UK).
4.9. Statistical Analysis
Statistical analysis was performed with SPSS Statistics by IBM Corporation, USA. We used unpaired
two-sample student′s t-test and log rank tests. p-values < 0.05 were considered statistically significant.
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